Document is current
Any future updates will be listed below
-
Authors
Cattinari, Maria Grazia
Pascual-Pascual, Samuel Ignacio
de Lemus, Mencía
Medina, Julita
Dumont, María
Rebollo, Pablo
Vázquez-Costa, Juan Francisco
-
Funding
Funding for this research was provided by:
Biogen Spain (PO 17947)
Novartis spain (Novartis spain)
Roche España (Roche España)
FundAME (FundAME)
- License Information
-
More Information
Article History
Received: 27 May 2024
Accepted: 22 May 2025
First Online: 4 June 2025
Declarations
:
: The study protocol was approved by the Ethics Committee of the “Hospital Clínico San Carlos” of Madrid (21/561-E). All participants provided their informed consent to participate in the registry.
: Not applicable.
: MGC has received support from Roche for attendance at scientific congresses. SIPP has received honoraria for conferences, consultancies, and participation in clinical trials with Biogen, Roche and Novartis outside the submitted work. ML has offered advisory support to Roche in the development of risdiplam. JM has received honoraria for conferences, consultancies, and participation in clinical trials with Biogen, PTC, Roche, and Avexis outside the submitted work. MD has no conflict of interest to declare. PR was an employee of IQVIA who received an honorarium from Fundame in connection with the development of this manuscript. JFVC is funded by grants of the Instituto de Salud Carlos III (JR19/00030, PI Vázquez) and received personal fees from Biogen and Roche outside the submitted work.
